Curis Inc (CRIS)

[Desert dweller]

Debio ASCO poster link

http://www.debiopharm.com/media/publications/72-debio-0932/3188-a-phase-i-study-of-debio-0932-an-oral-hsp90-inhibitor-in-patients-with-solid-tumors-.html


From the poster:

ANTI TUMOR ACTIVITY
• Anti-tumor activity could be assessed in 45/50 patients enrolled (5 patients had no evaluable
on-treatment disease assessment).
• Partial response was observed in 2 patients, one with NSCLC (see case history) and one
with breast cancer.
• Out of 8 patients with lung cancer, 1 had partial response, 4 had stable disease, and 3 had
progressive disease.

CASE HISTORY
• 63-year old Caucasian male.
• Diagnosis of Stage IV Kras-mutated adenocarcinoma of the lung in Nov 2007.
• Progressive disease after four regimens of systemic anti-cancer therapy, ending Aug 2009.
• Started Debio 0932 100 mg Q2D in July 2010.
• 40% reduction in target lesion diameter after 16 weeks of treatment (partial response).
• Response duration: 16 weeks.
• Treatment was well tolerated, with facial acneiform skin rash.

CONCLUSION
Debio 0932 was generally well tolerated at doses up to 1600 mg Q2D and 1000 mg QD
• Debio 0932 showed promising signs of anti-tumor activity in patients with advanced
solid tumors, especially in lung cancer
• The recommended Phase 2 dose (1000 mg QD) will be tested in an additional 30
patients in an ongoing expansion study
• A Phase I-II study of Debio 0932 in combination with standard of care in the first- and
second-line treatment of NSCLC is planned